676.00
-13(-1.89%)
Currency In JPY
Address
Marunouchi Center Building
Tokyo, 100-0005
Japan
Phone
81 3 5220 8950
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
988
First IPO Date
March 23, 2004
| Name | Title | Pay | Year Born |
| Mr. Kenji Mizutani | President, Chief Executive Officer & Representative Director | 0 | 1948 |
| Kazushi Takeda | Senior Executive Officer, Executive Vice President of F&A and Corporate Staff | 0 | N/A |
| Ryoji Tomokiyo | Executive Vice President of Business Development & Marketing | 0 | N/A |
| Mr. Toshiyuki Okada | Managing Executive Officer & Director | 0 | 1960 |
| Masayuki Ito | Executive Vice President & Head of Production | 0 | N/A |
| Yuji Shimojima | Executive Vice President of Overseas Subsidiaries & Medical Science | 0 | N/A |
| Mr. Yosuke Funakoshi | Senior Executive Officer, GM of Research & Development and Director | 0 | 1965 |
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.